Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease  by Reddy, P. Hemachandra & Shirendeb, Ulziibat P.
Biochimica et Biophysica Acta 1822 (2012) 101–110
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isReview
Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of
mitochondria, and selective synaptic degeneration in Huntington's disease
P. Hemachandra Reddy a,b,⁎, Ulziibat P. Shirendeb a
a Neurogenetics Laboratory, Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, 505 NW 185th Avenue, Beaverton, OR 97006, USA
b Department of Physiology and Pharmacology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA⁎ Corresponding author at: Neurogenetics Laborato
Oregon National Primate Research Center, Oregon Hea
NW 185th Avenue, Beaverton, OR 97006, USA. Tel.: +
418 2701.
E-mail address: reddyh@ohsu.edu (P.H. Reddy).
0925-4439/$ – see front matter © 2011 Elsevier B.V. All
doi:10.1016/j.bbadis.2011.10.016a b s t r a c ta r t i c l e i n f oArticle history:
Received 17 September 2011
Received in revised form 25 October 2011
Accepted 25 October 2011







Mitochondrial trafﬁckingHuntington's disease (HD) is a progressive, fatal neurodegenerative disease caused by expanded polygluta-
mine repeats in the HD gene. HD is characterized by chorea, seizures, involuntary movements, dystonia,
cognitive decline, intellectual impairment and emotional disturbances. Research into mutant huntingtin
(Htt) and mitochondria has found that mutant Htt interacts with the mitochondrial protein dynamin-
related protein 1 (Drp1), enhances GTPase Drp1 enzymatic activity, and causes excessive mitochondrial frag-
mentation and abnormal distribution, leading to defective axonal transport of mitochondria and selective
synaptic degeneration. This article summarizes latest developments in HD research and focuses on the role
of abnormal mitochondrial dynamics and defective axonal transport in HD neurons. This article also discusses
the therapeutic strategies that decrease mitochondrial fragmentation and neuronal damage in HD.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Huntington's disease (HD) is characterized by chorea, seizures,
involuntary movements, dystonia, cognitive decline, intellectual
impairment and emotional disturbances [1–4]. HD has an autosomal
dominant pattern of inheritance and an age-dependent penetrance.
HD occurs in 4–10 per 100,000 persons, mainly of Caucasian origin,
with mean age of onset at about 40 years. HD patients survive for
about 15–20 years from disease onset and diemainly due to complica-
tions from the disease. It is caused by polyglutamine (polyQ) repeat
expansion within the exon 1 of HD gene, that encodes an expanded
polyQ stretch in the huntingtin (Htt) protein (Fig. 1). Wild-type
(WT) and mutant Htt proteins are expressed ubiquitously in the
peripheral and central nervous systems of patients with HD. In the
postmortem brains of patients with HD, extensivemedium spiny neu-
ronal losswas observed in the striatum and also loss of pyramidal neu-
rons was observed in the cerebral cortex and hippocampus. Neuronal
loss has also been reported in the hypothalamus in postmortem brains
from HD patients and from HDmouse models [1,5–8], and Htt protein
aggregates have been found in pathological sites in the postmortem
brains of patientswith HD and of HDmousemodels [9–18]. The causes
of selective and premature death of medium spiny projection neuronsry, Division of Neuroscience,
lth & Science University, 505
1 503 418 2625; fax: +1 503
rights reserved.are not completely understood. Currently, there are no drugs or agents
available to treat or delay or prevent HD progression.
Over two decades of intense research using cell models, animal
models, and postmortem HD brains have implicated multiple cellular
changes in HD progression and pathogenesis. These changes include
transcriptional dysregulation, caspase activation, expanded polyQ
repeat protein interactions with other CNS proteins, NMDAR activa-
tion, calcium dyshomeostasis, defective axonal trafﬁcking, and abnor-
mal mitochondrial dynamics (e.g. increased ﬁssion and decreased
fusion) [19–23]. In studies focusing on abnormal mitochondrial
dynamics in HD, defective transport of mitochondria in axons and
selective synaptic degeneration were found to play a central role in
HD progression and pathogenesis.
The purpose of this article was to summarize the roles of mito-
chondrial dynamics and axonal transport in HD neurons. We will
also highlight the relationship between mutant Htt and mito-
chondrial dynamics, and between mutant Htt and dynamin-related
protein 1 (Drp1) — a mitochondrial protein that has been implicated
in causing mitochondrial fragmentation and abnormal distribution,
defective axonal transport of mitochondria and selective synaptic
degeneration in a variety of neurodegenerative diseases. We also
will discuss the therapeutic strategies that decrease mitochondrial
fragmentation and neuronal damage in HD.
2. Mutant huntingtin aggregates and oligomers in HD pathogenesis
HD was the ﬁrst among nine neurodegenerative diseases that had
expanded polyglutamine (polyQ) repeats as a dominant mutation in
Fig. 1. Schematic illustration of expanded polyQ repeats within exon 1 of Huntington's disease gene.
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peats within exon 1 of HD gene. In HD patients, the number of polyQ
repeats ranges from 36 to 120, whereas in healthy individuals, it
ranges from 6 to 35 [4,24]. In HD, polyQ repeats are highly polymor-
phic in general, and the onset of disease inversely correlates with
polyQ repeat length.
Htt is a 350 kDa protein, ubiquitously expressed in the peripheral
and central nervous systems (CNS) [25]. WT Htt is a cytosolic protein.
However, increasing evidence from postmortem HD brains and HD
mouse models revealed that a small part of mutant Htt is present in
subcellular organelles, including the nucleus, plasma membrane,
mitochondria, lysosomes, and endoplasmic reticulum [26–33]. Mutant
Htt is reported to interact with a large number of CNS proteins, and
this abnormal interaction ultimately leads to the gain of function of
mutant Htt in the progression of HD.
2.1. Mutant Htt aggregates
Mutant polyQ aggregates have been extensively reported in HD and
other polyQ repeat-associated diseases and responsible for disease
progression [4,34]. More recently, formations of oligomers, ﬁbrils, and
protoﬁbrils have been found in HD cell cultures and HD animal models,
including, ﬂies, worms and mice [35–39]. Mutant oligomeric proteins
are toxic and accumulate in neurons in an age-dependent manner.
These aggregates have been found to enter subcellular organelles,
such as mitochondria in neurons from patients with Alzheimer's
disease [40–45] and Parkinson's disease [46–52].
2.2. Mutant Htt oligomers
Recently, using cell culture systems, several investigators have
focused on developing molecules that inhibit oligomer formation
and apoptotic cell death [35,38,53–61]. Tremendous efforts are
underway in several laboratories across the world to reduce the
oligomer formation and toxicity.
Using immunostaining analysis of mutant Htt oligomers (detected
by the A11 antibody) [40], the Reddy lab recently found signiﬁcantly
increased numbers of mutant Htt oligomers in the cortical tissues
from postmortem brains of patients at stages HD3 and HD4, relative
to control subjects. These proteins ranged from 15 to 50 kDa [21].
Our immunostaining analysis of mutant Htt mitochondrial marker,
cytochrome oxidase 1 (COX1) revealed that mutant Htt oligomers
are colocalized with COX1, suggesting that mutant Htt oligomers
may promote mitochondrial toxicity, oxidative stress and neuronal
damage in HD patients [22]. Very recently, we [22] and others [23]
found mutant Htt interaction with the mitochondrial protein, Drp1
selectively in affected regions of the brain from the postmortem
brains of HD patients and BACHD transgenic mice, and in peripheral
cells from the brain tissues of HD patients (see upcoming section for
details).3. Cellular changes in Huntington's disease
The selective, premature death of striatal projection neurons
has been reported in HD patients and HD transgenic mice [1,2,
13–15,62]. As shown in Fig. 2, several cellular pathways have been
proposed and extensively investigated to explain premature neuronal
death in HD progression, but this neuronal death is not well under-
stood. The following cellular changes have been reported to involve
HD pathogenesis: 1) transcriptional dysregulation [63–66], 2) ex-
panded polyglutamine repeat proteins interacting with other CNS
proteins [67], 3) caspase activation [68–73], 4) NMDAR activation
[74–78], 5) calcium dyshomeostasis [28,79–85], and 6) abnormal
mitochondrial bioenergetics and axonal trafﬁcking [33,86–89]. The
most compelling evidence from these studies implicates abnormal
mitochondrial bioenergetics and defective axonal transport in the
selective synaptic degeneration and neuronal damage in HD.
4. Defective mitochondrial bioenergetics
Multiple lines of evidence suggest that abnormal mitochondrial
bioenergetics is involved in HD progression: 1) The loss of body weight
is a major factor in HD progression in HD patients and HD mouse
models [90–93]. 2) Studies using magnetic resonance imaging (MRI)
of postmortem brains from HD patients revealed a progressive atrophy
of the striatum, compared to brain images of age-matched control sub-
jects [94,95]. Several other studies of HD brains utilizing MRIs found
atrophy in the caudate nucleus, putamen, globus pallidus, and thalamus
[96–98]. 3) Using positron emission tomography in functional studies of
the brains of HD patients and control subjects, researchers found a
marked decrease in the amount of glucose utilized in the striatum
[99–103]. These same studies found decreased glucose metabolism to
correlate with reduced performance of HD patients on several cognitive
tasks, including immediate recall memory, verbal associative learning,
and executive functions, suggesting that cerebral glucose metabolism
is defective in HD patients [99–103]. 4) Biochemical studies of mito-
chondria in striatal neurons from brain tissues of late-stage HD patients
revealed reduced activity of several components of oxidative phosphor-
ylation, including complexes II, III, and IV of the electron transport
chain [86,87]. In studies of HD transgenic and knock-in mice, and in
experimental HD rodent models, decreases in enzyme activities of
complexes I, II, III, and IV were found in brain tissues [104], suggesting
that mitochondria are somehow involved in HD pathogenesis. And
5) recent studies of HD knock-in striatal cells and lymphoblasts
from HD patients revealed expanded polyglutamine repeats asso-
ciated with low levels of mitochondrial ATP and decreased mitochon-
drial ADP-uptake, suggesting that HD mutation is associated with
mitochondrial functional defects [105].
Overall, ﬁndings from these studies suggest that defective mito-
chondrial bioenergetics plays a large role in the progression and path-
ogenesis of HD.
Fig. 2. Cellular changes that have been implicated in Huntington's disease pathogenesis.
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Mitochondrial shape and structure are maintained by two impor-
tant but opposing forces: mitochondrial ﬁssion and mitochondrial
fusion [106–110]. Mitochondrial ﬁssion is the division of a single
mitochondrion into two, and mitochondrial fusion is the integration
of 2 mitochondria into single elongated mitochondrion. In a healthy
neuron, ﬁssion and fusion balance equally. Mitochondria alter their
shape and size to travel from the cell body to nerve terminals via
anterograde movement, and back to the cell body via retrograde
movement [19]. Mitochondrial ﬁssion and fusion are controlled by
evolutionarily conserved, large GTPases belonging to the family of
dynamin. Mitochondrial ﬁssion is regulated by mitochondrial ﬁssion
1 (Fis1) and Drp1. Fis1 is localized to the outermembrane of mito-
chondria. Drp1 is localized in the cytoplasm, but a small part of
Drp1 localized to the outermembrane, which promotes mitochondrial
fragmentation [110]. Mitochondrial fusion is controlled by 3 GTPase
proteins, 2 outermembrane proteins Mfn1 and Mfn2, and 1 inner
membrane protein Opa1 [107]. The C-terminal part of Mfn1 mediates
oligomerization among Mfn molecules of adjacent mitochondria
and facilitates mitochondrial fusion.
Increasing evidence suggests that mitochondrial dynamics is
imbalanced (increased ﬁssion and decreased fusion) in neurodegen-
erative diseases, including in AD [111–114], PD [110,115] and HD
[20–23]. This imbalanced mitochondrial dynamics is caused by an
altered expression of mitochondrial ﬁssion and fusion genes [110].
Further, in aged neurons, in neurons exposed to toxins, and in neu-
rons that express mutant proteins, such as mutant Htt, an imbalance
between ﬁssion and fusion leads to abnormalities in mitochondrial
structure and function, and neuronal damage [110].
Several studies reported such abnormal mitochondrial dynamics in
HD patients, HD mouse models, and cell lines that express mutant Htt
[20–23]. Recently, the Reddy lab studied abnormal mitochondrial
dynamics in tissues from postmortem brains of HD patients [21] and
primary neurons and brain tissues from BACHD transgenic mice [22].
In a study of brain specimens from patients at HD3 and HD4 stages
and from control subjects, we found increased expressions of Drp1
and Fis1 in HD4 than in HD3, and decreased levels of Mfn1, Mfn2, and
Opa1 in HD4 than in HD3 [21] in the striatum and cortex (HD-affected
brain regions), but not in the cerebellum (non-HD-affected brain
region), indicating that abnormal mitochondrial dynamics may berelated to HD [21]. Further, we also found signiﬁcantly increased levels
of cylophilin D (CypD) only in the striatum and cortex of the HD3 and
HD4 patients relative to control subjects [21], again suggesting structur-
ally damaged mitochondria in the HD-affected brain regions since
increased CypD is known to damage mitochondrial structure.
Using recently developed BACHDmice that express the full-length
(170 kb DNA) human Htt gene with 97 CAA and CAG (mixed repeats)
[8], we studied mutant Htt and mitochondrial and synaptic genes.
We found signiﬁcantly increased mRNA levels of ﬁssion genes, Drp1
and Fis1 and matrix gene CypD, and decreased levels of fusion
genes, Mfn1 and Mfn2 in 2-month-old BACHD mice relative to age-
matchedWTmice, suggesting that abnormal mitochondrial dynamics
is an early event in HD progression [22].
Overall, ﬁndings from our lab together with earlier study by Kim
et al. [20] indicate a relationship between mutant Htt and impaired
mitochondrial dynamics and dysfunction in HD.
5.1. Interaction between mutant Htt and Drp1, and elevated GTPase Drp1
enzymatic activity
To determine whether the interaction of Drp1 and mutant
Htt increases as HD progresses, the Reddy lab performed co-
immunoprecipitation analysis of Drp1 and mutant Htt, using a
Drp1 antibody, and immunoblotting analysis, using the mutant
Htt-speciﬁc antibody 1C2 and protein lysates of cortical tissues
from control subjects and HD3 and HD4 patients and protein lysates
from 2-month-old BACHD mice [22]. We found an 82 kDa and
40 kDa mutant Htt protein in IP elutes from HD3 and HD4 patients.
We also found Drp1 interaction with WT Htt, but lesser extent, in
the control subjects, indicating that mutant Htt interaction with
Drp1 is speciﬁc and related to disease progression.
Using cortical protein lysates from BACHD mice and WT mice, and
Drp1 and 1C2 antibodies, we also performed co-IP analysis. Similar to
HD brains, two bands of proteins, one with 82 kDa and the other with
40 kDa mutant Htt proteins were found in the IP elutes of the BACHD
mice, but not in those of the WT mice [22]. Overall, our lab ﬁndings
together with results from Song et al. [23] indicate that Drp1 interacts
with mutant Htt and may participate in mitochondrial fragmentation
and impaired mitochondrial biogenesis in HD neurons.
To determine whether Drp1 interaction with mutant Htt in
affected and unaffected brain tissues from HD patients and BACHD
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activity [22]. Interestingly, we found the signiﬁcantly increased levels
of Dp1 enzymatic activity in the cortex but not in the cerebellum of
HD3 and HD4 patients relative to control subjects. We also found
elevated levels of Drp1 enzymatic activity in the cerebral cortex and
striatum in the BACHDmice relative to theWTmice [22]. Our ﬁndings
are consistent with earlier ﬁndings from Song and colleagues who
found the increased Dp1 enzymatic activity in HD neurons [23].
Overall, recent evidence indicates that Drp1 interacts with mutant
Htt and enhances Drp1 enzymatic activity in HD-affected regions,
leading to synaptic and neuronal damage (see Fig. 3 for summary).
Further, we recently reported an increased interaction of Drp1 enzy-
matic activity, excessive mitochondrial fragmentation, and altered
mitochondrial distribution in neurons affected by AD [113]. We also
reported a similar ﬁnding in a study of HD, in which the interaction
of mutant Htt with Drp1 had similar consequences and this abnormal
interaction resulted in elevated Drp1 enzymatic activity, excessive
mitochondrial fragmentation, and altered mitochondrial distribution
in HD neurons [22]. These parallel ﬁndings for AD and HD suggest
a common pathway that may be involved in triggering abnormal
mitochondrial dynamics and selective neuronal damage.
6. Defective axonal transport of mitochondria in HD neurons
Normal axonal transport of organelles, including mitochondria,
synaptic vesicles, and proteins, is essential for synaptic activities and
neural communication. In diseased neurons, such as in HD neurons,
axonal transport is impaired mostly due to mutant proteins that
interact with proteins localized in axons. These abnormal interactions
block the transport of organelles along the axons, ultimately leading
to synaptic starvation. Studies of axonal transport reported impairedFig. 3. Schematic illustration showing mutant huntingtin interaction with mitocmitochondrial transport in cortical neurons overexpressed with
mutant Htt [89], in HD striatal neurons [88], in rat cortical neurons,
and in mouse striatal neurons transfected with N-terminal Htt [33].
Using live-cell imaging tools, primary neurons from BACHD
mice and WT mice, and DsRed-mito transfections, we analyzed the
mitochondrial motility in primary-neuron axonal projections from
BACHD and WT mice [22]. We found signiﬁcantly decreased motility
in the primary neurons from BACHD mice (20.88±4.86%) relative
to WT neurons (with 36.73±3.36%) (P=0.015). We also found
retrograde motility largely unaffected, and anterograde motility
greatly affected (WT neurons 21.58±2.42 and BACHD neurons
10.04±1.78, P=0.0009) [22].
Ours is the ﬁrst study that investigated mitochondrial mass, traf-
ﬁcking, anterograde and retrograde movements and synaptic viability
in primary neurons from BACHD mice. Our ﬁndings agree with a pre-
vious study [23], in which they studied mitochondrial transport in
neurons transfected with exon 1 containing 17, 46, and/or 97 polyQ
repeats. They found that neurons with exogenously expressed exon
1 Htt with 17 polyQ repeats exhibit ﬁlamentous, normal, and healthy
mitochondria, whereas neurons expressing exon 1 Htt with 46 polyQ
showed both elongated and round mitochondria. Neurons that exog-
enously expressed 97 polyQ repeats show mainly rounded, fragmen-
ted mitochondria. The ﬁndings from Song et al. [23] together with our
observations of mitochondrial trafﬁcking in BACHD mice, indicate
that mutant Htt with expanded polyQ repeats is responsible for
mitochondrial fragmentation in neurons affected by HD.
These ﬁndings also indicate that mutant Htt interaction with Drp1
may cause excessive mitochondrial fragmentation, leading to defec-
tive axonal transport and abnormal distribution of mitochondria in
BACHD mice. Fig. 4 summarizes data supporting excessive mitochon-
drial fragmentation and defective axonal transport of mitochondria.hondrial protein, Drp1 and subsequent pathogenic changes in HD neuron.
Fig. 4. Huntington's disease neuron showing excessive fragmentation of mitochondria, accumulation in cell soma, and abnormal distribution of mitochondria in neuronal processes
and synapses.
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Synaptic damage has been extensively reported in neuro-
degenerative diseases, including Alzheimer's [111–114,116,117],
Parkinson's [118–122] and Huntington's [22,23,123–127]. However,
the precise factors that cause synaptic degeneration are not
completely understood. Recent evidence from our lab [21,22] and
others [20,23] revealed that abnormal interaction of mutant Htt
with mitochondrial protein Drp1, causes excessive mitochondrial
fragmentation that leads to defective axonal transport and abnormal
mitochondrial distribution, particularly in neurites and synapse.
Synapses are the sites of high ATP demand, and reduced number of
mitochondria neurites and synapses produce low ATP and cause
synaptic degeneration in HD neurons. These events are summarized
above, and we now focus on synaptic damage and degeneration in
HD neurons.
To determine the effect of mutant Htt on synapses in HD, using
cortical tissues from BACHD mice and quantitative real-time RT-PCR, the Reddy lab measured mRNA levels of presynaptic protein,
synaptophysin and postsynaptic protein, PSD95 [22]. They found a
signiﬁcant reduction in the mRNA fold changes for the synaptic
genes, synaptophysin (−1.2 fold) and PSD 95 (−1.3 fold) relative
to WT mice.
Further, to determine the effects of mutant Htt on synaptophysin
and MAP2 levels, they also performed immunostaining analysis of
BACHD neurons using 10 DIV neurons from BACHD mice and WT
mice. They found signiﬁcantly decreased immunoreactivity of synap-
tophysin in the BACHD neurons relative to WT neurons [22]. Similar
to synaptophysin, immunoreactivity of MAP2 was signiﬁcantly de-
creased in the BACHD neurons relative to WT neurons, indicating
that mutant Htt may be involved in synaptic degeneration [22].
Overall, our recent studies of mitochondrial transport, mitochon-
drial dynamics, expression of synaptic genes in BACHD mice together
with earlier studies, indicate that synaptic damage is an early event in
disease process and may be linked to mutant Htt and abnormal
mitochondrial distribution at synapses in HD.
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Based on cellular changes observed in HD pathogenesis and pro-
gression, multiple therapeutic strategies have been developed and
tested in experimental cell, animal models, and even clinical trials,
to stop or delay disease progression. As shown in Fig. 5, these strate-
gies include: reducing mutant Htt allele expression (RNA silencing),
inhibit oligomer formation, inhibiting the interaction of polyQ with
other proteins in the central nervous system, enhancing the expres-
sion of endogenous transcription factors, enhancing autophagy,
increasing molecules that enhance axonal transport, reducing abnor-
mal mitochondrial dynamics, and increasing healthy mitochondrial
biogenesis.
8.1. Reducing mutant Htt allele expression
Extensive research revealed that soluble mutant Htt aggregates
and oligomers are toxic, and cause synaptic degeneration and neuro-
nal damage in HD. Therefore, reducing the expression of mutant Htt
allele is a direct and upstream approach to treat HD. This approach
involves silencing the post-transcriptional mutant Htt allele using
small, anti-sense RNA molecules. Currently, RNA silencing (shRNA)
technology is being used to reduce mutant Htt allele [128–136].
RNA silencing is tested in cell and mouse models of HD [137–139].
Further, delivery of short hairpin RNA using adeno-associated viral
(AAV) vectors is successful in HD truncated mice (N171-82Q). Mice
that received shRNA showed decreased mutant Htt aggregates
and improved rotorod performance and gait [140]. This approach
has been tested in BACHD mice and other mouse models. Further
research is still needed to target selectively mutant Htt allele in the
presence of both WT and mutant Htt alleles in HD neurons.
8.2. Inhibition of mutant oligomer formation
Several researchers around the world are using cell and animal
models, high throughput screening, and inhibitors of oligomers and
apoptotic cell death to determine molecules that reduce and/or
prevent mutant Htt oligomer formation in HD neurons [35,36,53–61].
8.3. Inhibiting the interaction between mutant Htt and mitochondrial
protein, Drp1
As described above, polyQ protein is sticky and likely to interact
with other CNS proteins [67] and participate in oligomers, ﬁbrils, pro-
toﬁbrils and ultimately ﬁbrillogenesis formation [35–39]. The soluble
mutant Htt aggregates are toxic and interact with axonal proteins,
including Drp1, impair axonal transport and cause synaptic degener-
ation. Regarding mutant soluble Htt aggregates and their interactionFig. 5. Possible therapeutic approacheswith Drp1, further research is still needed in order to determine
which domain of Drp1 protein interacts with mutant Htt aggregates
and causes mitochondrial fragmentation, and neuronal damage.
Therefore, identifying the molecules that inhibit abnormal interac-
tions between mutant Htt and Drp1 is an interesting therapeutic
approach.
8.4. Enhancing endogenous transcription factors (PGC1α and Nrf2)
Increasing evidence suggests that transcription factors, including
PGC1α and Nrf2, reduce mitochondrial oxidative damage and in-
crease neuronal survival, in general, and HD neurons, in particular
[141–143]. It is critical to increase endogenous levels of PGC1α and
Nrf2 in neurons affected by HD. Efforts are underway to enhance
endogenous transcription factors that protect neurons against mutant
Htt aggregates and oligomers and other oxidative insults.
8.5. Inactivating mTOR and enhancing autophagy
Growing evidence suggests that autophagy plays a large role
in clearing a cell's degraded proteins and organelles in HD neurons.
Further extensive literature on mammalian target of rapamycin
(mTOR) suggests that cells pre-treated with rapamycin are protected
against apoptotic cell death, particularly cells that express mutant
Htt [144–151]. Rapamycin, a lipophilic, macrolide antibiotic, induces
autophagy by inactivating the protein mTOR. Inhibition of mTOR
induces autophagy and reduces toxicity of polyglutamine expansions
in ﬂy and mouse models of HD [152]. Therefore, inactivation of mTOR
is another approach to treat patients with HD. Further research is still
needed to understand the role of autophagy, in HD.
8.6. Developing molecules capable of enhancing axonal transport
To improve axonal transport of mitochondria and other organ-
elles, molecules could be developed to enhance microtubule binding
capacity of ‘microtubule associated proteins with microtubules’ and
increase both anterograde and retrograde movements of organelles.
The tight microtubule binding of microtubule associated proteins
may enhance axonal transport of organelles, may provide and supply
necessary components and organelles to synapses and increase
synaptic outgrowth and neural communications.
8.7. Reduction of abnormal mitochondrial dynamics and increase of
healthy mitochondrial biogenesis
As discussed above, abnormal mitochondrial dynamics is an
emerging and key component in neuronal damage in HD [20–23,
109,110]. Maintaining the balance of mitochondrial dynamics is anfor Huntington's disease patients.
107P.H. Reddy, U.P. Shirendeb / Biochimica et Biophysica Acta 1822 (2012) 101–110important therapeutic strategy to protect neurons against the toxicity
of mutant Htt oligomers and oxidative insults [21]. It is equally im-
portant to maintain healthy mitochondrial biogenesis in HD neurons.
Recent research using primary neurons from AD transgenic mice and
mitochondria-targeted antioxidant, SS1 revealed that SS31 appears to
increase the numbers of healthy mitochondria and also anterograde
movement of mitochondria in primary neurons treated with SS31
[114].
9. The current status of experimental therapeutics in HD
Recent studies suggest that mitochondrial dysfunction and oxida-
tive stress are key players in HD progression and pathogenesis. To
reduce mitochondrial toxicity and abnormal mitochondrial dynamics
in HD neurons, we need to develop drugs that protect mitochondria.
In the last decade, several drugs have been tested in experimental
animal models of HD and also clinical trials. Several mitochondrial
drugs that act to protect neurons from mitochondrial damage, in-
cluding creatine, CoQ10 and resveratrol — have shown beneﬁcial
effects in cell and animal models. Creatine and CoQ10 have shown
deceased HD pathology and rotorod performance in R6/2 and N171-
82Q lines of HD mice. Findings from these studies suggest that crea-
tine and CoQ10 boost ATP levels and increase mitochondrial function
[153–156]. Further, resveratrol also has shown beneﬁcial effects in
the worm model of HD, and increased survival of striatal neurons
from knock-in mice indicating that resveratrol protect against age-
dependent mutant Htt toxicity in HD neurons [156].
Dimebon (or Dimebolin hydrochloride or atreperdine) is an anti-
histamine drug that has been used clinically in Russia to reduce cog-
nitive deﬁcits in AD patients [157]. Based on cell culture and murine
models of AD, phase III clinical trial was conducted in US and initial
ﬁndings were positive. However, a large-scale clinical trial did not
show signiﬁcant improved positive clinical symptoms in patients
with AD. Scientists from Medication, Inc., in collaboration with clini-
cians and researchers in North America, conducted phase III clinical
trials in HD patients, and the outcome was not positive [158,159].
These disappointing outcomes pose major challenge to HD patients
and researchers.
10. Conclusions and future directions
Mitochondrial dysfunction and oxidative stress are critical factors
in the development and progression of HD. Recent research revealed
that mutant Htt aggregates and oligomers appear to interact with
Drp1, to enhance GTPase Drp1 enzymatic activity, to increase mito-
chondrial fragmentation, and to cause abnormal mitochondrial dis-
tribution, ultimately leading to neuronal damage. These ﬁndings
suggest that abnormal mitochondrial dynamics and defective axonal
transport of mitochondria are mechanisms in HD pathogenesis.
In terms of therapeutic approaches, multiple approaches appear to
be promising, including silencing of mutant Htt allele, reducing oligo-
mer formation, enhancing endogenous levels of transcription factors
(PGC1α and Nrf2) and balancing mitochondrial dynamics and axonal
transport in neurons affected by HD. Recent experimental therapeu-
tics in cell and animal models are promising but no deﬁnitive drugs/
agents are available to treat HD patients. Further research is also
needed to better understand the mechanisms on how mutant Htt
aggregates and oligomers cause mitochondrial fragmentation and im-
pair axonal transport in HD neurons. Further, it is worth investigating
and developing the molecules that promote healthy mitochondrial
biogenesis, and increase axonal transport in neurons affected by HD.
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